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ThelimitedexpressionofN-GlycolylGM3(NeuGcGM3)gangliosideinhumannormaltissues,aswellasitspresenceinmelanoma
and breast carcinoma using 14F7 Mab (anti-NeuGcGM3), has been previously reported. In this work we evaluated for the ﬁrst
time the 14F7 Mab immunorecognition in some digestive system tumors. Immunohistochemical assays were made with 14F7,
followed by anti-mouse biotinylated antibody and ABC/HRP system in normal and pathological human tissues were made. No
immunoreaction was evidenced in normal tissues. The reactivity of 14F7 was detected in all adenocarcinomas of the stomach
(12/12), colon (12/12), and pancreas (11/11). A ﬁnely granular immunorecognition in esophageal tumors (5/15), epidermoid
carcinoma of the rectum (5/7), and basaloid carcinoma (4/5) of the latter as well as in hepatocellular carcinoma (13/14) was also
observed. Our results are in agreement with the assumption that NeuGcGM3 ganglioside may be considered as target for passive
and active immunotherapy in digestive system malignancies expressing this molecule.
1.Introduction
The digestive cancers are the ﬁrst cause of mortality
worldwide [1]. The most common malignancies of this
system are epidermoid carcinomas derived from oral cavity,
esophagus, and anal epithelium as well as adenocarcinomas,
originated mainly in esophagus, stomach, and colorectal
segment. Other neoplasms such as lymphomas, sarcomas,
and neuroendocrine tumors can be considered relatively rare
[2].
Despite of the signiﬁcant advances in cancer therapy,
the therapeutic options available for digestive tumors are
insuﬃcient. Particularly, ineﬀective treatments have been
applied in patients bearing pancreas, stomach, and liver
cancers. Patients with other malignancies such as colorectal
tumors have a longer life expectancy than those with the
before-mentioned cancers [3–5]. This fact promotes the
development of alternative treatment strategies using target
molecules.
Gangliosides, sialic acid-containing glycosphingolipids,
are considered attractive targets for cancer immunotherapy
and diagnosis based on their higher presence in tumors as
compared with normal tissues, as well as on their relevance
in tumoral growth [6].
The molecular basis for the absence of N-Glycolyl
neuraminic acid in human cells is due to a partial deletion in
thegenethatencodesCMP-Neu5Achydroxylase,theenzyme
responsibleforNeuGcbiosynthesis[7].However,theexpres-
sion of N-Glycolylated gangliosides has been reported in
several malignancies [8]. We reported the expression of2 ISRN Gastroenterology
N-Glycolyl GM3 (NeuGcGM3) ganglioside in breast tumors
by chemical analysis [9]. Later we generated the 14F7 Mab
highly speciﬁc against the NeuGcGM3 ganglioside that rec-
ognized breast inﬁltrating ductal carcinoma and melanomas
by immunohistochemistry [10]. We also demonstrated the
ability of 14F7 Mab labelled with 99mTc to recognize breast
tumors in vivo by the radioimmunoscintigraﬁc technique
[11].
The analysis of NeuGcGM3 expression in diﬀerent
human neoplasms could be useful in order to extend the
assessmentofthismoleculeastargetforcancerimmunother-
apy. Here, we present the 14F7 Mab immunohistochemical
recognitionindiﬀerenthumannormalandmalignanttissues
from digestive system, on both, gastrointestinal tract and
annex glands.
2.MaterialsandMethods
2.1. Monoclonal Antibody. 14F7 Mab (IgG1) a highly speciﬁc
anti- NeuGcGM3 ganglioside antibody was generated by
immunization of Balb/c mice with NeuGcGM3 hydrophobi-
cally conjugated with human very low-density lipoproteins
(VLDL) adjuvated with Complete Freud adjuvant (CFA).
This Mab was obtained by the hybridoma resulting of
the fusion of spleen cells with mouse myeloma cell line
P3X63Ag653 as described [10].
2.2. Tissue Specimens and Previous Processing. Sections of
archival formalin-ﬁxed and paraﬃn-embedded tissues from
72 primary human tumors from digestive system and 25 sec-
tionsofnormaltissueswereevaluatedbyimmunoperoxidase
staining.
2.3. Formalin-Fixed and Paraﬃn-Embedded Tissues. Rou-
tinely processed, formalin-ﬁxed and paraﬃn-embedded
archival tissue samples were taken from the pathology
department of Dr. “Manuel Fajardo” General Teaching
Hospital after it was approved by the clinical ethical com-
mittee. Five micrometer serial sections from each block were
obtained in a micrometer and mounted on plus slides (Dako
S2024, Carpinteria; USA). All sections were attached to the
slide by heating in a 70◦C oven for 1h. Afterwards the slides
were kept at room temperature until they were used.
The slides were dewaxed in xylene and rehydrated in
graded ethanol series as usual and endogenous peroxidase
activity was blocked with 0.03% hydrogen peroxide in abso-
lute methanol for 30 minutes. All sections were rehydrated
in distilled water for 10 minutes and rinsed with TBS,
and then incubated with Dako blocking protein solution
(Dako X0909, Carpinteria; USA) for 10 minutes at room
temperature to reduce nonspeciﬁc background staining.
2.4. Immunohistochemical Staining. Subsequently, slides
were placed in a humid chamber and incubated with
the primary mouse anti-NeuGcGM3 ganglioside 14F7 Mab
(10µg/mL) for 1h at room temperature. Negative controls
were performed substituting primary antibody for washing
Table 1: Immunorecognition of 14F7 Mab on normal digestive
system tissues.
Normal tissues No. cases Intensity Positive cells
Paraﬃn-embedded
Esophagus ND −−
Stomach 3/8∗ +/++ 1
Large intestine 0/9∗ − 0
Pancreas 0/4 − 0
Liver 0/4 − 0
ND: Not done, Intensity: − negative, + weak, ++ moderate, Positive cells:
0 (negative to less than 5%), 1 (6–25%), ∗samples from the normal tissue
located in peritumoral area.
buﬀer (TBS) and breast inﬁltrating ductal carcinoma was
used as positive control [10].
After two rinses in TBS, the tissues were incubated with
a rabbit anti-mouse IgG policlonal antibody (Dako E0354,
Carpinteria; USA) dilution 1:100 and with the avidin-
biotin/peroxidase complex (Dako K0355, Carpinteria; USA)
dilution 1:100 for 30 minutes each one. Among incubation
the slides were washed with TBS 1X for 10 minutes.
Enzymatic activity was visualized with DAB substrate
chromogen solution (Dako K3465, Carpinteria; USA) and
the samples were counterstained with Mayer’s Hematoxylin
(Dako S2020, Carpinteria; USA). Slides were dehydrated and
coverslipped with a synthetic mounting medium.
2.5. Evaluation. The intensity of reaction of each patient
tumor tissues was judged as negative (−), weak (+),
moderate (++), and strong (+++), and we used a com-
bination of this patterns to express intermediate levels of
immunostaining. The percentage of tumor cells showing
14F7 Mab immunoreactivity was estimated using 10x optical
microscopy ﬁelds selecting the most cellular regions of each
section, and it was classiﬁed as 0 (negative to less than 5%),
1 (6–25%), 2 (26–50%) and 3 (more than 50%). The results
in agreement with two diﬀerent observers were considered as
ﬁnal.
3. Results
3.1. Immunohistochemical Staining in Normal Tissues. The
results of 14F7 Mab immunoreactivity on some formalin-
ﬁxed and paraﬃn-embedded normal tissues from digestive
system (Stomach, Large intestine, Pancreas and Liver) are
showed in Table 1. No immunorecognition with 14F7 Mab
was observed, except for 3/12 (25%) of cases that showed a
weak to moderate 14F7 Mab reaction in some normal glands
located in peritumoral areas.
3.2. Immunohistochemical Staining in Neoplastic Tissues. The
results of 14F7 Mab immunoreaction on some primary
human tumors from gastrointestinal tract and annex glands
are showed in Table 2.ISRN Gastroenterology 3
Table 2: Immunorecognition of 14F7 Mab on some primary human tumors from digestive system.
Histopathological type No. cases (%) Intensity range Positive cells
Esophagus
Upper portion
Epidermoid Carcinoma 2/11 (18,2) +/+++ 1/2
Gastroesophageal junction
Epidermoid Carcinoma 1/2 (50) +++ 3
Adenocarcinoma 2/2 (100) +++ 3
Stomach (adenocarcinoma)
Well diﬀerentiated 7/7 (100) ++/+++ 3
Moderate diﬀerentiated 2/2 (100) +++ 3
Poorly diﬀerentiated 3/3 (100) ++/+++ 3
Large Intestine
Adenocarcinoma 12/12 (100) +/+++ 3
Rectum
Basaloid Carcinoma 4/5 (80) +/+++ 3
Epidermoid Carcinoma 5/7 (71,4) ++/+++ 3
Pancreas (adenocarcinoma)
Well diﬀerentiated 8/8 (100) ++/+++ 3
Poorly diﬀerentiated 3/3 (100) +++ 3
Liver
Hepatocellular carcinoma 13/14 (92,8) ++/+++ 3
Intensity: − negative, + weak, ++ moderate, +++ intense. Positive cells: 0 (negative to less than 5%), 1 (6–25%), 2 (26–50%), and 3 (more than 50%).
3.3. Gastrointestinal Tract
3.3.1. Esophagus. Around 30 percent of esophageal tumors
studied (5/15) were staining by 14F7 Mab (Table 2). Two
diﬀerent patterns of staining were observed in 2/11 tumor
samples from the upper portion of the esophagus. One
sampleshowedaweaktointenseandheterogeneousreaction
located mainly in cellular clusters (Data no shown), while
the second pattern was observed as the same pattern of
recognition of the lower portion of the esophagus. Moreover,
bothsamplesshowedsmallerpercentageofpositivecellsthan
other tissues (Figure 1). The samples belonging to the lower
portion of the esophagus exactly in the gastroesophageal
junction exhibited a weak to intense, homogeneous and
ﬁnely granular reaction located in cell membrane and
cytoplasm in more than 75% of epithelial cells on 3/4 (75%)
of cases (Figure 1).
3.3.2.Stomach. Amoderatetointense immunoreactionwith
14F7 Mab was observed in more than 95% of malignant cells
from the glandular epithelium (12/12) of this organ. The
immunoreaction not related to the grade of diﬀerentiation
(P = .27 by CHI-SQUARE Test). The immunorecognition
of this Mab was observed on membrane and cytoplasm of
theabovementionedcells,althoughamembranepatternwas
also evidenced (Figure 1). The staining was homogeneous
andﬁnelygranular.Additionally,3/12(25%)ofcasesshowed
a 14F7 Mab reaction in some normal glands located in
peritumoral areas. The pattern of staining was homogeneous
and ﬁnely granular in 2/12 cases and heterogeneous in 1/12
cases.
3.3.3.Colon. Colonic adenocarcinomasexhibited ahomoge-
neous and ﬁnely granular reaction with 14F7 Mab in 12/12.
Theintensityofthisreactionvariedfromweaktointenseand
was observed in more than 75% of malignant glandular cells.
The staining was mainly located in the plasmatic membrane
and also in the cytoplasm of the above mentioned cells.
T h i sp a t t e r no fe x p r e s s i o nw a sd e t e c t e di n9 / 1 2( 7 5 % )o f
studied cases (Figure 2). A heterogeneous immunostaining
with 14F7 Mab in 3/12 (25%) cases was evidenced.
3.3.4. Rectum. Basaloid carcinoma showed a weak to intense
reaction in more than 70% of neoplastic cells. This
immunorecognitionwaslocatedinplasmaticmembraneand
cytoplasm of these cells in 4/5 (80%) of cases (Figure 2).
A moderate to intense reaction with 14F7 Mab was
observed in 5/7 (71, 4%) of epidermoid carcinoma tested.
This recognition was evidenced homogeneous and ﬁnely
granular in more than 90% of tumor cells, and it was located
in the plasmatic membrane and cytoplasm of these cells
(Figure 2).
3.4. Annex Glands
3.4.1. Liver. A moderate to intense immunostaining with
14F7 Mab was observed in more than 90% of tumor cells
in 13/14 (92, 8%) of hepatocellular carcinomas. The recog-
nition of this Mab was located in membrane and cytoplasm
of neoplastic hepatocytes showing a homogeneous and ﬁnely
granular pattern (Figure 3). Just one case of hepatocellular
carcinoma showed a weak to moderate reaction.4 ISRN Gastroenterology
(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 1: Hematoxylin and eosin staining of well-diﬀerentiated carcinoma of esophagus (a), adenocarcinoma of gastroesophageal junction
(d), and gastric adenocarcinoma (g). Immunorecognition of 14F7 Mab in before-mentioned tumors (b, e, h). Note a moderate (ﬁnely
granular) and strong reactivity located on plasmatic membrane and cytoplasm of malignant epithelial cells. For negative controls (c, f, i),
tissues were stained as described in Section 2 without 14F7 Mab. No staining occurred in control sections. Black bar = 50µm.
3.4.2. Pancreas. The 14F7 Mab immunoreacted strongly
with more than 80% of pancreatic neoplastic cells in the
poorly diﬀerentiated adenocarcinomas tested (3/3). The
staining was located mainly on the plasmatic membrane of
malignant cells although the cytoplasm was also reactive.
Well-diﬀerentiated adenocarcinomas showed a moderate
to intense immunostaining located in the membrane and
cytoplasm in more than 90% of tumor cells in 8/8 (Figure 3).
Two patterns of recognition were evidenced in pancreas
malignancies: the ﬁrst, homogeneous and ﬁnely granular;
the second, homogeneous and little grosser. The intensity of
immunoreaction with 14F7 Mab was not related to the grade
of diﬀerentiation (P = .72 by Fisher’s Exact Test).
4. Discussion
The changes in carbohydrate pattern expression associated
with the oncogenic transformation of the cells have been
described for certain types of tumors [6, 12]. Usually neo-
plastic cells exhibit aberrant overexpression of gangliosides
present or not in normal adult tissues becoming attractive
targets for immunotherapy [13, 14].
Aberrant and elevated expression of gangliosides has
been previously demonstrated on the surface of tumors
derived from some stomach, pancreas, and large intestine
as compared with cells of the normal tissues. Moreover, the
majority of the studies of gangliosides expression in human
malignancies have been restricted to N-Acetylated variant of
sialic acid [6, 15–17].
N-Glycolyl neuraminic acids residues are considered not
to be expressed in human normal tissues [18] due to the
inactivation of the gene for CMP-Neu5Ac hydroxylase, the
enzyme responsible for NeuGc biosynthesis [7]. However,
small levels of expression have been found in some normal
human tissues (e.g., epithelial cells and their secretions) [10,
19, 20]. The preferential expression in human malignancies
have been related with the incorporation of N-GlycolylISRN Gastroenterology 5
(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 2: Hematoxylin and eosin staining of colonic adenocarcinoma (a), basaloid carcinoma (d), and epidermoid carcinoma (g) of the
rectum. Strong immunostaining was detected on colonic adenocarcinoma (b) and epidermoid carcinoma of the rectum (h), while basaloid
carcinoma of the rectum was weakly reactive (e) with 14F7 Mab. No staining occurred in all negative controls studied (c, f, i). Black bar =
50µm.
neuraminic acids residues from dietary sources due to the
altered and more accelerated metabolism of neoplastic cells
[19, 20]. Others have also suggested an alternative pathway
for the synthesis of Neu5Gc hydroxylase despite that normal
human cells do not have a metabolic pathway for the
production of N-Glycolyl neuraminic acids residues [21].
The antigenic determinant of Hangnutziu Deicher (HD)
antigen is N-Glycolyl neuraminic acid [22]. Several studies
with speciﬁc antibodies against HD antigen or anti- N-
Glycolylated gangliosides antibodies have been reported in
malignant tissues [9, 10, 23].
The 14F7 Mab recognition is strictly limited to N-
Glycolyl function so it is able to diﬀerentiate between N-
Glycolyl and N-Acetyl variants of GM3 ganglioside [10].
GM3 constitutes a normal component of the plasmatic
membrane of normal human cells [10, 22, 24]. In our study
we observed a cytoplasmatic reactivity of 14F7 Mab showing
both ﬁnely and grosser granular pattern. These results could
be supported by the dynamics intracellular movement of
glycosphingolipids within the diﬀerent subcellular compart-
mentsaswellastheirrecyclingfromtheplasmaticmembrane
to Golgi apparatus where they may be remodeled [25, 26].
Both pancreatic carcinoma and gastric adenocarcinoma
confers one of the highest mortality rates in malignant
humantumors[1].Regardlesstheadvanceswithsomedrugs,
these neoplasms are two of the most lethal cancers and
constitute an enormous challenge to clinicians and cancer
scientists in order to diagnose and treat them. Here, we
showed the reactivity of 14F7 Mab in all, diﬀerentiated or
not, pancreatic carcinomas. A similar pattern was observed
in gastric adenocarcinomas where 14F7 staining was not
related to the grade of diﬀerentiation. These results could
be relevant in order to consider NeuGcGM3 ganglioside as
potential target in these two diseases, orphan of eﬀective
therapies.
It is known that squamous cell and adenocarcinomas
are responsible for more than 95 percent of all esophageal
carcinomas [2]. In our study the majority of the squamous6 ISRN Gastroenterology
(a) (b) (c)
(d) (e) (f)
Figure 3: Hematoxylin and eosin staining of hepatocellular carcinoma (a) and pancreatic adenocarcinoma (d). See a strong and ﬁnely
granular immunoreactivity of 14F7 Mab on both malignant hepatocytes (b) and glandular malignant cells derived from pancreas (e). The
reaction was located on plasmatic membrane and cytoplasm. No staining occurred on negative controls sections (c and f, resp.). Black bar =
50µm.
cell carcinoma from the upper esophagus was not stained
with 14F7 Mab. However, a similar staining pattern in one
of squamous cell carcinomas located in the gastroesophageal
junction regarding gastric cancer was evidenced in our
data, despite the diﬀerences in the cellular lineage that
originated from the malignant neoplasm. Additionally, the
adenocarcinomas of gastroesophageal junction showed a
similar staining of the rest gastric tumors.
Zhang et al. [6] described the GM2 expression in gastric,
pancreatic, and colonic tumoral biopsies by immunohisto-
chemical studies using 696 Mab (IgM, anti-GM2 ganglioside
antibody). While Diatlovitskaia et al. [16]r e p o rt e dam a r k e d
increase in the content of absolute gangliosides in gastric
tumors regarding normal tissues, using biochemical and
speciﬁc anti sera methods. Additionally, they found that
GM3, GD3, and GM1 are the predominant gangliosides in
most of the cases, whereas several polar components are
minor ones. On the other hand, the expression of little
amountsofGM3lactoneingastrictumors,anditsabsencein
normaltissueshasbeenreported [17]asw ellastheincr eased
amount of GM3 and GD3 gangliosides in colorectal and
pancreatic carcinoma [15]. Recently, Distler et al. [27]p u b -
lishedtheexpressionofCD75s-1-ganglioside(IV(6)Neu5Ac-
nLc4Cer) and the structurally closely related iso-CD75s-
1-ganglioside (IV(3)Neu5Ac-nLc4Cer) by immunohistology
of cryosections and semiquantitative thin layer chromatog-
raphy (TLC) of tissue lipid extracts combined with mass
spectrometry. These gangliosides have been considered as
potential targets for adjuvant therapy in pancreatic can-
cer.
Here, we described the 14F7 (a highly speciﬁc IgG1
against NeuGcGM3) recognition in all colonic adenocarci-
nomas. More of 50% of the malignant cells were positive
(moderate to intense immunostaining in 90% of tumors).
While only 75% of rectum tumors were recognized by 14F7.
The expression of N-Glycolyl neuraminic acid containing
ganglioside in colonic cancers has been previously described
by some authors [17, 22, 28, 29]. Higashi et al. [22]
demonstrated the major presence of molecular species as
NeuGcGM3, 4-O-acetyl NeuGcGM3, and NeuGcGM2 in the
ganglioside fraction of some samples of colon tumors by
TLC immunostaining, whereas no antigenic compound was
detectedinnormaltissues.Ontheotherhand,Hirabayashiet
al. [28] conﬁrmed the expression of NeuGcGM2 ganglioside
incoloniccancersbytwodimensionalTLCimmunostaining.
Additionally, Watarai et al. [29] reported the expression
of i-active ganglioside N-Glycolylated in colonic malignant
tissues by immunohistochemical procedures using SHS-1
antibody speciﬁc against this antigen.
Primary tumors of liver are the sixth most common
cancer in the world and the third most common cause
of death attributable to cancer. Most of these tumors are
hepatocellular carcinomas [30]. Outstandingly, we obtained
here a moderate to intense staining in more than 50% of
positive cells in 13/14 cases of formalin-ﬁxed and paraﬃn-
embedded cancer tissues using 14F7 Mab. The detection
o fH a n g n u t z i uD e i c h e ra n t i g e nb yﬂ o wc y t o m e t r yi n3 / 1 5
patients with hepatocellular carcinoma was published by
Koda et al. [23]. Later, the same group demonstrated the
increase of NeuGc expression in hepatocellular carcinomaISRN Gastroenterology 7
cells when tyramide signal ampliﬁcation method was used.
This technology was useful for the immunohistochemical
detection of low levels of the HD antigens in cryosections of
these tumors [31].
Previously we reported the NeuGcGM3 ganglioside bio-
chemical measure by mass spectrometry and TLC immunos-
taining with monoclonal antibodies that recognized anti-N-
Glycolylated epitope of sialic acid (P3) [8] or Hanganutziu
Deicher[9].Additionally,ourgrouppublishedthe14F7Mab
immunorecognition in primary melanomas and melanomas
metastases as well as in human breast inﬁltrating ductal
carcinoma [10, 32]. Later, the expression of NeuGcGM3
ganglioside in human breast cancer was supported by
radioimmunoscintigraphic technique using the 14F7 Mab
labeled with 99mTc where positive images indicating spe-
ciﬁc uptake of 99mTc-14F7 radioimmunoconjugate were
obtained. This study permitted to visualize for the ﬁrst time
the recognition “in vivo” of 14F7 Mab in human breast
primary tumors [11].
Moreover,inpreclinicalstudiestreatmentwith14F7Mab
produced a strong antitumoral activity inducing cytotoxicity
dependentandindependentofcomplement[33,34]suggest-
ing that NeuGcGM3 should be considered as one attractive
target for active and passive immunotherapy in digestive
malignancies expressing this molecule.
The roles of NeuGcGM3 ganglioside on tumoral pro-
gression as well as its suppressor properties have been
previous described [35, 36]. In addition, Labrada et al. [37]
showed a consistent increase of NeuGcGM3 expression in
the metastatic lesions as compared with primary tumors
using the 3LL-D122 Lewis Lung Carcinoma spontaneous
metastasis murine model. Our data and the relevance of
NeuGcGM3 suggest that the expression of this molecule
could be related with the aggressive behavior of digestive
malignant cells. However, we did not distinguish changes
in the level of NeuGcGM3 expression associated with
histopathological grade in stomach and pancreas tumors.
In summary, this study reports the immunohistochem-
ical recognition of 14F7 Mab, a highly speciﬁc antibody
against NeuGcGM3 ganglioside, in some malignant tissues
derived from digestive system but not in normal sections.
These data could support the possible use of NeuGcGM3
as target in digestive tumors. The mortality related to these
cancers is expected to increase by 2020 [38]. NeuGcGM3
therapy targeting could be an eﬀective approach to face that
challenge. Clinical trials with NeuGcGM3/VSSP molecular
cancer vaccine [39] and 1E10 ( an anti-idiotypic Mab
that mimicry NeuGcGM3 ganglioside [40] are ongoing in
metastatic breast cancer patients and advanced nonsmall cell
lung cancer, respectively.
5. Conclusions
The expression of NeuGcGM3 in some malignant tissues
derived from digestive system but not in normal sections
suggest that the expression of this ganglioside could be
related to the aggressive behavior of malignant cells from
digestive tumors. Our data could support the possible
use of NeuGcGM3 as target for both active and passive
immunotherapy of digestive system tumors expressing this
molecule.
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